X0202 SCHEDULE 13G/A 0001839947 XXXXXXXX LIVE 2 Common Stock, par value $0.001 per share 06/30/2026 0001411685 Vistagen Therapeutics, Inc. 92840H400 343 Allerton Avenue South San Francisco CA 94080 Rule 13d-1(c) TCG Crossover GP I, LLC b DE 0 740101 0 740101 740101 N 1.8 OO These securities are held of record by TCG Crossover I (as defined in Item 2(a) below). TCG Crossover GP I (as defined in Item 2(a) below) is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities. Consists of (i) 334,573 shares of Common Stock (as defined in Item 2(d) below) issuable upon exercise of certain Tranche I Warrants (as defined and described in the Issuer's Prospectus Supplement filed with the United States Securities and Exchange Commission (the Commission)) pursuant to Rule 424(b)(5) on October 3, 2023 (the Prospectus)), and (ii) 405,428 shares of Common Stock issuable upon exercise of certain Tranche II Warrants (as defined in the Prospectus, together with the Tranche I Warrants, the Warrants). The Warrants contain a provision which prohibits the exercise of the Warrants to the extent that doing so would result in the holder of the Warrants (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates) beneficially owning more than 9.99 percent of the shares of Common Stock then outstanding immediately after giving effect to such exercise (the Beneficial Ownership Limitation). As of the date of this filing, the Reporting Persons (as defined in Item 2(a) below) hold less than the Beneficial Ownership Limitation in the aggregate. Based on 41,772,554 shares of Common Stock, as follows: (a) 41,032,453 shares of Common Stock outstanding as of June 12, 2026, as reported by the Issuer (as defined in Item 1(a) below) in its annual report filed with the Securities and Exchange Commission (the Commission) on June 15, 2026 (the Form 10-K), plus (b) an aggregate of 740,101 shares of Common Stock issuable upon exercise of the Warrants held of record by TCG Crossover I. TCG Crossover Fund I, L.P. b DE 0 740101 0 740101 740101 N 1.8 PN These securities are held of record by TCG Crossover I. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP I and may be deemed to share voting, investment and dispositive power with respect to these securities. Consists of (i) 334,573 shares of Common Stock issuable upon exercise of Tranche I Warrants and (ii) 405,428 shares of Common Stock issuable upon exercise of Tranche II Warrants. The Warrants contain a provision which prohibits the exercise of the Warrants due to the Beneficial Ownership Limitation. As of the date of this filing, the Reporting Persons hold less than the Beneficial Ownership Limitation in the aggregate. Based on 41,772,554 shares of Common Stock, as follows: (a) 41,032,453 shares of Common Stock outstanding as of June 12, 2026, as reported by the Issuer in the Form 10-K, plus (b) an aggregate of 740,101 shares of Common Stock issuable upon exercise of the Warrants held of record by TCG Crossover I. TCG Crossover GP II, LLC b DE 0 2220303 0 2220303 2220303 N 5.1 OO These securities are held of record by TCG Crossover II (as defined in Item 2(a) below). TCG Crossover GP II (as defined in Item 2(a) below) is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. Consists of (i) 1,003,718 shares of Common Stock issuable upon exercise of Tranche I Warrants and (ii) 1,216,585 shares of Common Stock issuable upon exercise of Tranche II Warrants. The Warrants contain a provision which prohibits the exercise of the Warrants due to the Beneficial Ownership Limitation. As of the date of this filing, the Reporting Persons hold less than the Beneficial Ownership Limitation in the aggregate. Based on 43,252,756 shares of Common Stock, as follows: (a) 41,032,453 shares of Common Stock outstanding as of June 12, 2026, as reported by the Issuer in the Form 10-K, plus (b) an aggregate of 2,220,303 shares of Common Stock issuable upon exercise of the Warrants held of record by TCG Crossover II. TCG Crossover Fund II, L.P. b DE 0 2220303 0 2220303 2220303 N 5.1 PN These securities are held of record by TCG Crossover II. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities. Consists of (i) 1,003,718 shares of Common Stock issuable upon exercise of Tranche I Warrants and (ii) 1,216,585 shares of Common Stock issuable upon exercise of Tranche II Warrants. The Warrants contain a provision which prohibits the exercise of the Warrants due to the Beneficial Ownership Limitation. As of the date of this filing, the Reporting Persons hold less than the Beneficial Ownership Limitation in the aggregate. Based on 43,252,756 shares of Common Stock, as follows: (a) 41,032,453 shares of Common Stock outstanding as of June 12, 2026, as reported by the Issuer in the Form 10-K, plus (b) an aggregate of 2,220,303 shares of Common Stock issuable upon exercise of the Warrants held of record by TCG Crossover II. Chen Yu b X1 0 2960404 0 2960404 2960404 N 6.7 IN These securities are held of record by TCG Crossover I and TCG Crossover II. TCG Crossover GP I is the general partner of TCG Crossover I and may be deemed to have voting, investment, and dispositive power with respect to the securities held of record by TCG Crossover I. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to the securities held of record by TCG Crossover II. Chen Yu is the sole managing member of each of TCG Crossover GP I and TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to the securities held of record by TCG Crossover I and TCG Crossover II. Consists of (i) 334,573 shares of Common Stock issuable upon exercise of Tranche I Warrants held of record by TCG Crossover I, (ii) 405,528 shares of Common Stock issuable upon exercise of Tranche II Warrants held of record by TCG Crossover I, (iii) 1,003,718 shares of Common Stock issuable upon exercise of Tranche I Warrants held of record by TCG Crossover II, and (vi) 1,216,585 shares of Common Stock issuable upon exercise of certain Tranche II Warrants held of record by TCG Crossover II. The Warrants contain a provision which prohibits the exercise of the Warrants due to the Beneficial Ownership Limitation. As of the date of this filing, the Reporting Persons hold less than the Beneficial Ownership Limitation in the aggregate. Based on 43,992,857 shares of Common Stock, as follows: (a) 41,032,453 shares of Common Stock outstanding as of June 12, 2026, as reported by the Issuer in the Form 10-K, plus (b) an aggregate of 2,960,404 shares of Common Stock issuable upon exercise of the Warrants held of record by TCG Crossover I and TCG Crossover II. Vistagen Therapeutics, Inc. 343 Allerton Avenue, South San Francisco, CA 94080 This Amendment No. 2 (Amendment No. 2) amends and supplements the Schedule 13G initially filed with the Commission on October 16, 2023, as amended by Amendment No. 1 filed with the Commission on May 15, 2026 (the Original Schedule 13G) and is being filed by TCG Crossover Fund I, L.P. (TCG Crossover I), TCG Crossover GP I, LLC (TCG Crossover GP I), TCG Crossover Fund II, L.P. (TCG Crossover II) and TCG Crossover GP II, LLC (TCG Crossover GP II and together with TCG Crossover I, TCG Crossover GP I and TCG Crossover II, the Reporting Entities) and Chen Yu (the Reporting Individual). The Reporting Entities and the Reporting Individual are collectively referred to as the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached as Exhibit 1 to the Original Schedule 13G. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Amendment No. 2 except to the extent of such Reporting Person's pecuniary interest therein. The address of the principal business office of each Reporting Person is 245 Lytton Ave., Suite 350, Palo Alto, CA 94301. TCG Crossover GP I and TCG Crossover GP II are each a limited liability company organized under the laws of the State of Delaware. TCG Crossover I and TCG Crossover II are each a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America. Y See Row 9 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein. See Row 11 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein. See Row 5 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein. See Row 6 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein. See Row 7 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein. See Row 8 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein. Y N Under certain circumstances set forth in the limited partnership agreements of TCG Crossover I and TCG Crossover II and the limited liability company agreements of TCG Crossover GP I and TCG Crossover GP II, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. TCG Crossover GP I, LLC /s/ Craig Skaling 08/14/2026 TCG Crossover Fund I, L.P. /s/ Craig Skaling 08/14/2026 TCG Crossover GP II, LLC /s/ Craig Skaling 08/14/2026 TCG Crossover Fund II, L.P. /s/ Craig Skaling 08/14/2026 Chen Yu /s/ Craig Skaling 08/14/2026